4-HO-MPMI, also known as 4-hydroxy-N-methyl-(α,N-trimethylene)tryptamine or as lucigenol, is a psychedelic drug of the pyrrolidinylmethylindole and cyclized tryptamine families.
Interactions
Pharmacology Pharmacodynamics
The affinity (Ki) of 4-HO-MPMI for the serotonin 5-HT2A receptor has been found to be 13nM. It produces psychedelic-appropriate responding in animal tests with similar potency as DOI. The drug has two enantiomers, with only the (R)-enantiomer being active.
Chemistry Analogues Analogues of 4-HO-MPMI include MPMI, 5-MeO-MPMI, 5F-MPMI, CP-135,807, 4-HO-McPeT, 4-HO-pyr-T, and SN-22, among others.
History 4-HO-MPMI was developed by the team led by David E. Nichols from Purdue University in the late 1990s.
Society and culture Legal status Canada 4-HO-MPMI is not a controlled substance in Canada as of 2025.
See also Pyrrolidinylmethylindole Cyclized tryptamine MSP-2020
References
External links Lucigenol (4-HO-MPMI) – Isomer Design Lucigenol Info - Hip Forums